Summary
Abivax SA (ABIVAX) is a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic vaccines and anti-viral compounds. The companys technologies are based on RNA-protein interaction Interference, B cell and cytotoxic TH1 cell amplification. ABIVAXs clinical stage products include ABX203, a vaccine for chronic hepatitis B; and ABX464, a small molecule against HIV. In addition to this, it also offers ABX196, an adjuvant candidate for vaccination which is under phase 1 clinical trial.
GlobalData's Abivax SA (ABVX) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.
Abivax SA Key Recent Developments:
Sep 20,2016: ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results
Sep 15,2015: ABIVAX appoints Antonino Ligresti, MD and Dominique Costantini, MD to its Board of Directors
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
